source
- Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head testThe results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.BioPharma Dive · 1mo ago↗ source
- Ethyreal starts up with $101M and takes aim at a pair of immune diseasesThe startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.BioPharma Dive · 1mo ago↗ source
- Sanofi stops immune drug trial in latest research setbackThe failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a potential blockbuster.BioPharma Dive · 1mo ago